Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects

NCT02621489 · Completed

Last updated 2026-05-28

This clinical trial is testing whether adding Bydureon to insulin treatment helps heal the inner lining of blood vessels in people with type 2 diabetes who have undergone stent placement.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 38 people

Who can join Ages 18–80 · all sexes

Timeline Started 2015-12 · est. completion 2022-10

Where 1 site · Sweden

What this study is testing ClinicalTrials.gov NCT02621489 ↗

Description as written by the study sponsor.

The aim of the study is to use Exenatide long-acting release (LAR) \[Bydureon\] to minimize vascular remodeling and neointima formation after Percutaneous Coronary Intervention (PCI) and to accelerate stent endothelialisation.

Treatments tested

Bydureon also known as Exenatide Drug

2 mg Once Weekly
Humulin kwickpen also known as Insulin Aspart Drug

Humulin kwickpen 10U QD at bedtime
Metformin also known as Biguanide Drug

Metformin 1g BID

Main thing measured	The degree of non-covered stent struts by Bydureon add on to Insulin over that of Insulin as analyzed by optical coherence tomography (OCT).
Sponsor	Karolinska Institutet
Conditions studied	Atherosclerosis, Diabetes, Restenosis
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02621489 ↗